Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis
Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis
The present pilot study constitutes a proof-of-principle in the use of a quantitative LC-MS/MS based proteomic method for the comparative analysis of representative low-grade breast primary tumor tissues with and without metastases and metastasis in lymph node relative to the nonmetastatic tumor type. The study method incorporated iTRAQ stable isotope labeling, two-dimensional liquid chromatography, nanoelectrospray ionization and high resolution tandem mass spectrometry using the hybrid QqTOF platform (iTRAQ-2DLC-MS/MS). The principal aims of this study were (1) to define the protein spectrum obtainable using this approach, and (2) to highlight potential candidates for verification and validation studies focused on biomarkers involved in metastatic processes in breast cancer. The study resulted in the reproducible identification of 605 nonredundant proteins (p ? 0.05). A quantitative comparison revealed 3/3 proteins with significantly increased/decreased level in metastatic primary tumor and 13/6 proteins with increased/decreased level in lymph node metastasis compared to nonmetastatic primary tumor (p < 0.01). Changes in selected differentially expressed proteins were verified with qRT-PCR. Although our pilot scale study does not warrant general biological conclusions, the synergic regulation of some proteins with related function (e.g., heme binding proteins, proteins of energetic metabolism, interferon induced proteins, proteins with adhesive function) determined in our sample set reflects the ability of our method in providing biologically meaningful data. The main conclusion from this pilot study was that our quantitative proteomic method constitutes a novel way of analyzing cancerous breast tissue biopsy samples that can be extended as part of a larger scale biomarker discovery program.
362-373
Bouchal, Pavel
49baebee-1916-457d-983d-7f93a348c601
Roumeliotis, Theodoros
f1284c98-b5eb-483e-9416-594c678e62fd
Hrstka, Roman
b08b0f63-7d4c-4c7d-a90f-454db4dd57ed
Nenutil, Rudolf
21fcec7b-87ec-44a8-bf1c-1e673cb1bfed
Vojtesek, Borivoj
3a9074e5-0f44-4604-bfba-ca0426cb926b
Garbis, Spiros D.
7067fd19-50c9-4d42-9611-f370289470bd
January 2009
Bouchal, Pavel
49baebee-1916-457d-983d-7f93a348c601
Roumeliotis, Theodoros
f1284c98-b5eb-483e-9416-594c678e62fd
Hrstka, Roman
b08b0f63-7d4c-4c7d-a90f-454db4dd57ed
Nenutil, Rudolf
21fcec7b-87ec-44a8-bf1c-1e673cb1bfed
Vojtesek, Borivoj
3a9074e5-0f44-4604-bfba-ca0426cb926b
Garbis, Spiros D.
7067fd19-50c9-4d42-9611-f370289470bd
Bouchal, Pavel, Roumeliotis, Theodoros, Hrstka, Roman, Nenutil, Rudolf, Vojtesek, Borivoj and Garbis, Spiros D.
(2009)
Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis.
Journal of Proteome Research, 8 (1), .
(doi:10.1021/pr800622b).
Abstract
The present pilot study constitutes a proof-of-principle in the use of a quantitative LC-MS/MS based proteomic method for the comparative analysis of representative low-grade breast primary tumor tissues with and without metastases and metastasis in lymph node relative to the nonmetastatic tumor type. The study method incorporated iTRAQ stable isotope labeling, two-dimensional liquid chromatography, nanoelectrospray ionization and high resolution tandem mass spectrometry using the hybrid QqTOF platform (iTRAQ-2DLC-MS/MS). The principal aims of this study were (1) to define the protein spectrum obtainable using this approach, and (2) to highlight potential candidates for verification and validation studies focused on biomarkers involved in metastatic processes in breast cancer. The study resulted in the reproducible identification of 605 nonredundant proteins (p ? 0.05). A quantitative comparison revealed 3/3 proteins with significantly increased/decreased level in metastatic primary tumor and 13/6 proteins with increased/decreased level in lymph node metastasis compared to nonmetastatic primary tumor (p < 0.01). Changes in selected differentially expressed proteins were verified with qRT-PCR. Although our pilot scale study does not warrant general biological conclusions, the synergic regulation of some proteins with related function (e.g., heme binding proteins, proteins of energetic metabolism, interferon induced proteins, proteins with adhesive function) determined in our sample set reflects the ability of our method in providing biologically meaningful data. The main conclusion from this pilot study was that our quantitative proteomic method constitutes a novel way of analyzing cancerous breast tissue biopsy samples that can be extended as part of a larger scale biomarker discovery program.
This record has no associated files available for download.
More information
e-pub ahead of print date: 20 November 2008
Published date: January 2009
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 341680
URI: http://eprints.soton.ac.uk/id/eprint/341680
ISSN: 1535-3893
PURE UUID: 57576bb4-f046-4e1b-a926-509ba8cd4849
Catalogue record
Date deposited: 02 Aug 2012 15:14
Last modified: 14 Mar 2024 11:43
Export record
Altmetrics
Contributors
Author:
Pavel Bouchal
Author:
Theodoros Roumeliotis
Author:
Roman Hrstka
Author:
Rudolf Nenutil
Author:
Borivoj Vojtesek
Author:
Spiros D. Garbis
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics